Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. by Cheng, Susan et al.
UC San Diego
UC San Diego Previously Published Works
Title
Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health 
and Disease: A Scientific Statement From the American Heart Association.
Permalink
https://escholarship.org/uc/item/3744f9nf
Journal
Circulation. Cardiovascular genetics, 10(2)
ISSN
1942-325X
Authors
Cheng, Susan
Shah, Svati H
Corwin, Elizabeth J
et al.
Publication Date
2017-04-01
DOI
10.1161/hcg.0000000000000032
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
AHA Scientific Statement
e1
Abstract—Through the measure of thousands of small-molecule metabolites in diverse biological systems, metabolomics 
now offers the potential for new insights into the factors that contribute to complex human diseases such as cardiovascular 
disease. Targeted metabolomics methods have already identified new molecular markers and metabolomic signatures of 
cardiovascular disease risk (including branched-chain amino acids, select unsaturated lipid species, and trimethylamine-N-
oxide), thus in effect linking diverse exposures such as those from dietary intake and the microbiota with cardiometabolic 
traits. As technologies for metabolomics continue to evolve, the depth and breadth of small-molecule metabolite profiling 
in complex systems continue to advance rapidly, along with prospects for ongoing discovery. Current challenges facing 
the field of metabolomics include scaling throughput and technical capacity for metabolomics approaches, bioinformatic 
and chemoinformatic tools for handling large-scale metabolomics data, methods for elucidating the biochemical structure 
and function of novel metabolites, and strategies for determining the true clinical relevance of metabolites observed in 
association with cardiovascular disease outcomes. Progress made in addressing these challenges will allow metabolomics 
the potential to substantially affect diagnostics and therapeutics in cardiovascular medicine. (Circ Cardiovasc Genet. 
2017;10:e000032. DOI: 10.1161/HCG.0000000000000032.)
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Substantial technical advances have enabled robust and comprehensive profiling of molecular markers in the 
study of human health and disease. These advances have 
led to refinement in the application of genomic, epigen-
etic, transcriptomic, proteomic, and metabolomic tools in 
clinical studies designed to elucidate disease pathobiol-
ogy, to identify clinically relevant biomarkers, and to guide 
therapy. Metabolomics, among the most recently emerged 
“omics” fields, involves the systematic measure and study 
of small-molecule metabolites across biological systems 
using biosamples that include plasma, urine, saliva, and tis-
sues. Metabolomics serves as a reflection of gene and pro-
tein functional activity and, in doing so, captures information 
that is proximal to a given disease phenotype while spanning 
the spectrum from genetic sequence to cellular physiology. 
Therefore, metabolomics offers the potential to complement 
other cellular measures, including the vast genetic information 
derived from DNA sequencing in humans. Notably, whereas 
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the genetic sequence is largely static from birth, metabolomic 
measures are relatively dynamic, representing cellular activ-
ity and the effects of extrinsic exposures, including dietary 
intake, physical fitness, microbiota variation, and toxicant 
exposures. The ability to integrate measures of both intrinsic 
and extrinsic origin, as well as their interplay, may effectively 
bridge investigations of both gene and environment and will 
be critical for understanding complex, multifaceted human 
diseases such as cardiovascular disease (CVD). Accordingly, 
the rich small-molecule metabolite data represented by an 
individual’s metabolome, along with the chemical diversity 
of population-scale metabolomes, could lead to key pathobio-
logical insights and offer powerful tools for personalizing risk 
assessment and disease prevention. In this American Heart 
Association scientific statement, we aim to provide an over-
view of the rapidly evolving field of metabolomics, its appli-
cations to date for understanding CVD, and its future role in 
biomedicine. Instead of comprehensively reviewing technical 
metabolomics, which has been offered by prior reports, we 
sought herein to highlight for the scientific community the key 
issues and challenges relevant to the application of metabo-
lomics, including those related to metabolite standards, data-
bases and identification, study design, bioinformatics, and 
clinical translation.
Metabolomics Approaches
A range of technical approaches have been used for the 
analysis of metabolites in biospecimens, including nuclear 
magnetic resonance (NMR) and mass spectrometry (MS). 
These analytical tools have been extensively reviewed 
elsewhere.1,2 Although each tool has its own strengths and 
detractions, both are capable of assaying metabolites in a 
number of biofluids and tissues. NMR typically requires 
minimal sample processing and provides absolute quanti-
tation of analytes, but it is limited by sensitivity and thus 
generally allows measurement of only the most abundant 
of metabolites. By contrast, MS-based metabolomics can 
involve direct infusion into a mass spectrometer or, more 
routinely, coupling to upfront chromatography, either liq-
uid chromatography (LC) or gas chromatography, to reduce 
sample complexity before mass analysis. Additionally, 
both LC-MS and gas chromatography–MS require sample 
preparation with extraction of metabolites from complex 
specimens and, in many cases, even chemical processing 
before assay. Necessary preprofiling procedures notwith-
standing, MS-based approaches offer a much greater range 
of detection with high sensitivity, allowing the measure of 
up to thousands of small molecules at a given time. Such 
MS-based approaches may be operated either in a “tar-
geted” fashion, with detection of prespecified molecules 
(typically up to 100–200 metabolites at a time), or as part 
of an “untargeted” full scan, in discovery mode without 
prespecification of molecules (typically measuring >1000 
molecules at a time). Thus, advancing from NMR to tar-
geted MS to untargeted MS approaches provides increasing 
analytical coverage and hence greater discovery potential. 
However, with a greater number of measures come addi-
tional analytical and computational hurdles. These chal-
lenges include those pertaining to alignment of data to 
allow comparison of specific metabolites across hundreds 
to thousands of samples, handling and extraction of large 
spectral data files, and ultimately the definitive identifica-
tion of metabolites of interest (discussed below in Current 
Applications).
Metabolomics Discoveries in CVD
Although still early in its technical and scientific evolution, 
metabolomics and its application to the study of clinical CVD 
have already demonstrated substantial potential for discovery 
and insight.
Metabolite Correlates of CVD
An overview of clinical studies of metabolomics in CVD is 
provided in Table 1. Early metabolomics studies made use 
of NMR-based approaches to distinguish individuals with 
multivessel coronary artery disease (CAD) from individuals 
without angiographic CAD using spectral fingerprint pat-
terns.3 Although initially promising with reportedly >90% 
predictive power for identifying patients with CAD from 
control subjects, spectral fingerprint data were in hindsight 
more reflective of sex and statin medication use than inde-
pendent correlates of CAD.4 These results underscore the 
need for comprehensive follow-up to identify signatures 
of a potential cause rather than a consequence of disease, 
careful chemistry to annotate metabolite peaks, and statisti-
cal evaluation of potential confounders that can influence 
dynamic metabolomic signals. A later study used a targeted 
tandem MS (MS/MS) approach to identify and quantify 69 
metabolites in individuals with angiographic CAD, reveal-
ing higher levels of branched-chain amino acids (BCAAs) 
in association with CAD even after adjustment for car-
diovascular risk factors.7,13 Subsequently, high-throughput 
NMR measures of 68 abundant plasma metabolites, per-
formed in a multicohort epidemiological study (including 
the National Finnish FINRISK study, Southall and Brent 
Revisited Study, and British Women’s Health and Heart 
Study), showed that higher phenylalanine and monoun-
saturated fatty acid levels were associated with increased 
CVD risk, whereas higher concentrations of omega-6 fatty 
acids and docosahexaenoic acid were associated with lower 
risk of CVD over a follow-up period spanning decades. 
Importantly, these observations were validated not only 
in multiple independent cohorts but also with orthogonal 
targeted MS approaches applied to an additional 2000 
participants from the Framingham Offspring Study, dem-
onstrating the potential for generalizability and validity of 
metabolomic observations.16
Untargeted, also known as nontargeted, MS-based analyses 
have now extended the measure from several dozen to several 
thousand metabolites in a single sample. Recent applications 
of LC-MS have identified 4 unsaturated lipids (lysophosphati-
dylcholine 18:1, lysophosphatidylcholine 18:2, monoglyceride 
18:2, and sphingomyelin 28:1) in association with CVD inde-
pendently of traditional risk factors in the TwinGene cohort; 
these findings were then validated in the ULSAM (Uppsala 
Longitudinal Study of Adult Men) and PIVUS (Prospective 
Investigation of the Vasculature in Uppsala Seniors) cohorts.14 
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Table 1. Major Findings to Date From Selected Clinical Studies of Metabolomics and Cardiovascular Disease
Study Study Design and Size Method Major Findings
Brindle et al3 (2002) Case-control: n=36 patients with triple-
vessel disease compared with n=30 
patients with normal coronaries
NMR Case-control: PLS-DA (80% training set, 20% test set) 
demonstrated the most discriminating analytes to be lipids, 
mostly VLDL, LDL, HDL, and choline
Cross-sectional: n=76 patients with CAD 
with 1-, 2-, or 3-vessel disease
Cross-sectional: NMR chemical shifts of δ1.30 and δ3.22 
(representing LDL variants and other lipid elements) discriminated 
CAD severity, whereas traditional clinical risk factors did not
Kirschenlohr et al4 (2006) Cross-sectional: n=322 patients with normal 
coronaries or 1-, 2-, or 3-vessel CAD
NMR Predictions for CAD presence were only 80% correct for patients 
not treated with statins and 61% for treated patients
Lewis et al5 (2008) Experimental: n=36 planned MI patients Targeted LC-MS Experimental: metabolites involved in pyrimidine metabolism, 
TCA cycle, and the pentose phosphate pathway were altered 
after planned MI
Cross-sectional: 12 acute MI patients; 9 
non-CAD patients
Cross-sectional: aconitic acid, hypoxanthine, TMAO, and 
threonine distinguished presence vs absence of spontaneous MI
Turer et al6 (2009) Experimental: n=37 patients undergoing 
CABG
Targeted LC-MS Lower extraction rates of acetylcarnitine and 3-hydroxybutyryl-
carnitine by the myocardium were observed after intraoperative 
reperfusion
Shah et al7 (2010) Cross-sectional and prospective: n=757 
patients total (3 groups of CAD case-
control pairs)
Targeted LC-MS Cross-sectional: BCAAs and urea cycle metabolites were 
associated with presence of CAD in derivation and validation 
cohorts
Prospective: dicarboxylacylcarnitines predicted incident CAD events
Wang et al8 (2011) Cross-sectional: n=1876 patients 
undergoing elective cardiac catheterization
Targeted LC-MS Higher levels of TMAO, choline, and betaine were associated with 
presence of CVD
Shah et al9 (2012) Prospective: n=2023 patients undergoing 
elective cardiac catheterization
Targeted LC-MS Long-chain dicarboxylacylcarnitines, BCAAs, and fatty acids were 
associated with death or MI
Medium-chain acylcarnitines were also associated with death
Koeth et al10 (2013) Cross-sectional and prospective: n=2595 Targeted LC-MS Higher L-carnitine in plasma was associated with prevalent CVD 
and incident coronary, stroke, and mortality events in individuals 
with concurrently high TMAO levels
Tang et al11 (2013) Prospective: n=4007 patients undergoing 
elective cardiac catheterization
Targeted LC-MS Higher baseline TMAO was associated with major adverse 
cardiovascular event (death, MI, or stroke)
Zheng et al12 (2013) Prospective: n=1744 blacks Targeted LC-MS Two unknown novel metabolites were associated with incident 
heart failure in multivariable models: dihydroxy-docosatrienoic 
acid and an isoform of either hydroxyleucine or hydroxyisoleucine
Bhattacharya et al13 
(2014)
Cross-sectional: n=1983 patients with no 
vs significant CAD
Targeted LC-MS Two distinct PCA-derived metabolite factors were associated 
with both CAD presence and CAD severity in adjusted models: 1 
factor was composed of BCAA and the other was composed of 
short-chain acylcarnitines
Ganna et al14 (2014) Prospective: n=3668 from 3 separate 
derivation and replication cohorts
Untargeted MS Four metabolites were associated with incident CAD: 
lysophosphatidylcholine 18:1, lysophosphatidylcholine 18:2, 
monoglyceride 18:2, and sphingomyelin 28:1
Monoglyceride 18:2 showed association with an SNP in the 
ZNF259/APOA5 region with a weak but positive causal effect in 
mendelian randomization analysis
Jové et al15 (2015) Prospective and cross-sectional: n=131 
patients with TIA in derivation and n=162 
in validation cohorts
Targeted LC-MS Prospective: low lysophosphatidylcholine (16:0) was associated 
with increased stroke risk
Cross-sectional: lower levels of lysophosphatidylcholine (20:4) 
and lysophosphatidylcholine (22:6) also demonstrated potential 
risk for stroke or atherosclerosis
Würtz et al16 (2015) Prospective multicohort: n=7256 
derivation; n=2622 and n=3536 replication
NMR and targeted 
LC-MS
Four metabolites were associated with incident CVD in meta-
analyses: higher phenylalanine and monounsaturated fatty acids, 
lower omega-6 fatty acids, and docosahexaenoic acids
BCAA indicates branched-chain amino acid; CABG, coronary artery bypass graft; CAD, coronary artery disease; CVD, cardiovascular disease; HDL, high-density 
lipoprotein; LC, liquid chromatography; LDL, low-density lipoprotein; MI, myocardial infarction; MS, mass spectrometry; NMR, nuclear magnetic resonance; PCA, 
principal components analysis; PLS-DA, partial least-squares discriminant analysis; SNP, single-nucleotide polymorphism; TCA, tricarboxylic acid; TIA, transient 
ischemic attack; TMAO, trimethylamine-N-oxide; and VLDL, very low-density lipoprotein. 
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Using alternative untargeted LC-MS approaches, others have 
assessed thousands of metabolite features in a small cohort 
of CVD cases and controls; the metabolite trimethylamine-
N-oxide (TMAO) was observed to be highly associated with 
CAD, and this finding was validated in multiple large cohorts 
in models adjusting for clinical risk factors.8,11 Interestingly, 
TMAO was found to be produced by the interaction of gut 
bacteria with dietary intake of phosphatidylcholine and car-
nitine, components typically overrepresented in a meat-based 
diet.8,10,17 Furthermore, supplementation with TMAO or inter-
mediary metabolites involved in the production of TMAO, 
including γ-butyrobetaine, was found to promote atheroscle-
rosis formation in mice.8,18 Although the exact mechanisms 
underlying the atherosclerosis-promoting effects of TMAO 
and related metabolites have yet to be defined, initial work 
has suggested that TMAO may regulate sterol metabolism and 
promote macrophage foam cell formation.8
Collectively, the breadth and depth of metabolomics 
studies conducted over the past decade have begun to reveal 
previously unappreciated factors that may contribute to the 
pathogenesis of CVD, including dietary factors and gut micro-
biota variation. As the number of human investigations with 
metabolomics profiling data available has expanded, studies 
have begun to associate circulating metabolites not only with 
global CVD outcomes7,9 but also with specific CVD subtypes, 
including myocardial ischemia and infarction,5 congestive 
heart failure,6,12 and stroke.15
Metabolite Correlates of Cardiometabolic  
Risk Factors
Overall, CVD represents a complex collection of multifacto-
rial disease states and risk factors. Thus, to complement the 
study of the end-disease phenotypes, extensive complemen-
tary efforts have been made to understand the pathophysiol-
ogy of more well-circumscribed risk factors. As seen in other 
“omics” fields, research focused on individual CVD risk fac-
tors can yield more specific information on potential pathways 
to disease progression. For instance, metabolomics studies of 
traditional risk factors have identified both plasma and uri-
nary metabolite correlates of blood pressure and hypertension. 
These include amino acids such as alanine,19,20 hippuric acid 
derivatives of gut microbial activity,19,21 and hexadecanedio-
ate, a dicarboxylic acid that has also been associated with 
mortality.22 Given the established importance of lipids (includ-
ing triacylglycerides and cholesterol-based species) to CVD 
pathobiology, lipidomic correlates of conventional choles-
terol subfractions (eg, high-density lipoprotein, low-density 
lipoprotein, and very low-density lipoprotein) have also been 
the subject of multiple investigations.23–26 Studies to date have 
demonstrated varying degrees of intercorrelation among lipid 
species, underscoring the potential of lipidomic variation to 
shed important insights into cardiovascular risk that are not 
reflected by traditional lipid measures alone.27,28
Perhaps the most consistent and developed finding with 
respect to cardiometabolic risk traits has been the link between 
BCAAs with insulin resistance and type 2 diabetes mellitus. 
BCAAs and related metabolites have been associated with 
insulin resistance in several cohorts,29–31 and an investigation 
in the Framingham Heart Study observed that baseline levels 
of circulating BCAAs predicted the development of diabetes 
mellitus up to 12 years later.32 In another study, BCAA lev-
els were found to decrease more after bariatric surgery than 
after behavioral weight loss, even for an equivalent amount of 
weight lost,33 paralleling the greater impact of surgical weight 
loss on glucose homeostasis. Furthermore, BCAAs appear 
lower in metabolically healthy versus metabolically unwell 
overweight/obese individuals34 and can predict improve-
ment in insulin resistance with weight loss.35 Studies in rats 
suggest that dietary supplementation of high-fat diets with 
BCAAs can promote insulin resistance regardless of weight 
gain.29 In humans, changes in circulating BCAA levels have 
been independently associated with CVD, adding further to 
the growing body of data pointing to common metabolic dis-
turbances giving rise to both diabetes mellitus and CVD.7,13 
Although the mechanistic underpinnings of these findings 
to date remain unclear, recent work has raised the intrigu-
ing possibility that elevated BCAAs may originate from gut 
microbiota rather than from endogenous sources. In identical 
twins discordant for obesity,36 fecal microbiota transplanta-
tion from the obese twin into germ-free mice led to increased 
total body and fat mass and the development of obesity-asso-
ciated metabolic phenotypes; these results stood in contrast 
to those in mice transplanted with microbiota from the lean 
twin.36 Transplantation of microbiota from obese twins was 
also associated with increased expression of genes involved 
in metabolism of BCAAs and higher BCAA levels in serum, 
again offering support for a possible unifying source of risk 
for obesity, diabetes mellitus, and CVD.
Metabolomics research has also focused on lifestyle 
behaviors that can alter the natural history of CVD, including 
exercise- and diet-based interventions, given their pleiotro-
pic role in attenuating the effects of multiple traditional risk 
factors. Anticipating that metabolite profiles will differ on 
the basis of the timing and duration of physical activity, both 
short-term and long-term studies have sought to characterize 
the biochemical response to exercise. Early studies by Lewis 
et al have shown that the acute response to an exercise stress 
test involves an increase in plasma markers of glycogenoly-
sis, lipolysis, and adenine nucleotide catabolism, in addition 
to an increase specifically in concentrations of amino acids, 
span 2 tricarboxylic acid cycle intermediates, and niacina-
mide, a modulator of insulin release and glycemic control.37 
Metabolite changes after prolonged exercise (ie, marathon 
running) have been correlated with a further increase in mark-
ers of lipolysis, an increase in products of ketogenesis, and 
a marked downturn in concentrations of most amino acids. 
Huffman et al38 studied previously sedentary individuals 
undergoing 6 months of aerobic exercise and observed that 
inactive overweight to obese adults who underwent exercise 
training had improved insulin sensitivity that was associated 
with increased plasma glycine, proline, and alanine levels, 
as well as increased concentrations of free fatty acids and 
products of fatty acid oxidation. More recently, studies of 
adult twin pairs and age- and sex-matched pairs of unrelated 
adults have found that more active individuals have better 
lipoprotein cholesterol profiles and higher levels of polyun-
saturated relative to saturated fatty acids.39 Corroborating 
the findings from studies of cardiometabolic disease and 
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diabetes mellitus, Kujala et al39 also found that the BCAA 
isoleucine was lower in active than inactive individuals, with 
similar findings for valine, tyrosine, and phenylalanine. With 
respect to diet, comparatively fewer investigations have been 
reported, in part because of the relatively greater challenge 
of analytically disentangling nutrient from nonnutrient sig-
nals detectable in biofluids.40 Nonetheless, a recent experi-
mental study demonstrated the potential of a high-choline or 
L-carnitine diet in mice to inhibit intestinal microbial pro-
duction of trimethylamine,41 a previously reported correlate 
of cardiometabolic risk. Follow-up preclinical and human 
studies are needed to further clarify the potential for dietary 
changes to induce metabolomic variation that, in turn, affects 
clinical outcomes.
Moving forward, it will be important for all study results 
to be validated by independent groups in different clini-
cal populations, to delineate causality of CVD risk-related 
metabolites in experimental models, and to define the bio-
logical mechanisms by which these metabolites either pro-
mote or attenuate atherogenesis. For metabolites meeting 
this high bar, it will be essential to determine whether their 
dietary or pharmacological modulation alters both metabo-
lomic signatures and the associated natural history of CVD 
in humans. In addition to shedding light on fundamental 
mechanisms of disease, changes in the human metabolome 
may serve as indicators of how efficacious a given cardio-
vascular intervention may be and could even elucidate the 
molecular basis for such efficacy (ie, pharmacometabolo-
mics).42 Kitzmiller et al43 demonstrated that multiple meta-
bolic pathways, including those involving the microbiome, 
potentially contribute to the low-density lipoprotein cho-
lesterol lowering efficacy and the pleiotropic effects of 
simvastatin. Another study investigating the differential 
response of hypertensive patients to the β-blocker atenolol 
demonstrated that the variability in metabolic pathways is 
a function of race and genotype.44 Although still early in its 
infancy, pharmacometabolomics could prove important for 
personalizing CVD therapy.
Current Applications
Although broad-scale metabolomics assays have not been 
approved by the US Food and Drug Administration for 
clinical purposes, MS is routinely used under US Food and 
Drug Administration approval to measure a variety of select 
compounds or metabolites in clinical laboratories, as shown 
in Table 2. The main criteria required to deploy an assay in 
clinical practice are safety and efficacy. A review of the US 
Food and Drug Administration’s perspective on clinical MS 
provides several examples of pathways leading to approved 
diagnostic tests.45 In the research setting, metabolomics data 
have been used primarily to classify different populations with 
respect to presence or absence of disease or with respect to 
risk for disease. For metabolomics to be used in the clinical 
setting for individual patients, substantial evidence will be 
required to demonstrate that metabolomics data are indeed 
effective for providing either a diagnosis or information that 
will optimize therapy. Some of the potential requirements for 
transitioning metabolomics from a research to a clinical prac-
tice application are shown in the Appendix.
A key issue concerning the possible future translation of 
metabolomics from research to clinical practice is the fact 
that most laboratory data used for patient care involve quan-
tification of results expressed as concentration units (absolu-
tion quantification); most metabolomics data are currently 
expressed as a percent increase/decrease relative to a refer-
ence population (relative quantification). In the clinical labo-
ratory, quantitative measurements are very tightly controlled. 
By contrast, metabolomics data are collated, analyzed, and 
reported from different laboratories using a variety of methods. 
Accordingly, quality control systems for relative quantifica-
tion need to be developed before metabolomics can transition 
to routine clinical practice. One approach to this challenge 
could be to develop quantification relative to an analyte that 
is present in all samples, as is currently done when quantify-
ing the percent of glycated hemoglobin for monitoring dia-
betes mellitus therapy. Nonetheless, controlling data from 
multiple different sources also poses challenges with regard 
to standardized analytical practices. Thus, for metabolomics 
to migrate from a research application to a patient care appli-
cation, major investments in infrastructure will be required. 
An example of this kind of structure is the Clinical Proteomic 
Tumor Analysis Consortium of the National Cancer Institute 
for developing proteomics platforms.46
Study Design and Technical Considerations
The challenges pertaining to translation notwithstanding, 
several key study design and technical considerations are 
also required for successful implementation of metabolomics 
approaches in research (Table 3). The type of study subjects, 
size of the study cohort, and availability of appropriate control 
subjects are all important factors for evaluating the extent to 
which there is adequate statistical power for detecting asso-
ciations between metabolites and a given outcome of inter-
est (Data Analyses and Data Reporting below). Investigators 
should also carefully review the quality of the collection and 
storage of biospecimens for proposed metabolomics profil-
ing because some types of analytes may be at risk for at least 
partial degradation under certain sample handling conditions. 
Because variation in metabolites may be related to a range of 
exogenous and endogenous factors, data collection on study 
subjects should ideally include information about medication 
use, dietary patterns, and environmental exposures, as well as 
concomitant clinical conditions.
With respect to the technical aspects of metabolomic pro-
filing, it should be decided at the outset whether a targeted 
or untargeted approach will be used, along with the most 
appropriate quality control methods. If a targeted approach is 
selected, the extent to which candidate analytes will be mea-
sured as part of a hypothesis-driven analysis should be pre-
specified. For example, if BCAAs and acylcarnitines are to be 
analyzed to test a given hypothesis, a variety of targeted ana-
lytical platforms are available, including commercial kits that 
can provide validated quantitative values. Given their feasibil-
ity and accessibility, targeted MS approaches have been used 
in the majority of CVD studies published to date. However, 
studies geared toward generating novel hypotheses or discov-
ering disease-stage specific biomarkers are more likely to ben-
efit from an untargeted approach that offers the simultaneous 
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measurement of all detectable metabolites in a given biospeci-
men. Because of the widespread availability and robustness of 
accurate mass spectrometers, such instruments are often used 
for study designs based on untargeted metabolomics. Notably, 
an untargeted approach does not exclusively require accurate 
mass analyses that provide part-per-million mass accuracy. 
In fact, biomarker discovery and biomarker identification 
can logically be separated into 2 different objectives within a 
given research study. For example, a multitargeted method for 
specific compounds could be used in conjunction with untar-
geted (full scan) data acquisitions with a nominal mass instru-
ment. After identification of metabolites of potential clinical 
importance, an in-depth secondary analysis can be conducted 
with an accurate mass instrument. Furthermore, although 
untargeted analysis is generally considered unbiased, as is the 
case with virtually all scientific approaches, it too is inherently 
biased with respect to the types of metabolites (ie, hydropho-
bic versus hydrophilic) extracted from complex specimens 
given the use of specific organic solvents and the chemical 
class of molecules assayed with specific chromatography 
techniques. For example, if an LC reversed-phase C18 col-
umn is used, hydrophilic compounds will not be well retained. 
Such an untargeted method would be unable to distinguish the 
Table 2. Current Routine Uses of Mass Spectrometry in the 
Clinical Laboratory
Type of Test Test Description
FDA-approved in vitro diagnostic 
tests
LC-MS/MS for quantification of 
tacrolimus
LC-MS/MS for newborn screening
MALDI-TOF for microbial 
identifications
Laboratory-developed tests: 
routinely used
GC-MS and LC-MS/MS for drugs of 
abuse confirmation
GC-MS and LC-MS/MS for 
monitoring pain management 
compliance
LC-MS/MS for quantifying steroids
LC-MS/MS for monitoring 
immunosuppressants
LC-MS/MS for quantifying vitamin D 
and related metabolites
Laboratory-developed tests: 
specialized assays (partial list)
Amino acid analysis
Heavy-metal analysis
Light-chain analysis
Metanephrine analysis
Methylmalonic acid quantification
Novel psychoactive substances
Parathyroid hormone–related 
protein
Quantification of thyroglobulin
Renin
Therapeutic drug monitoring
Thyroid hormone
FDA indicates US Food and Drug Administration; GC, gas chromatography; 
LC, liquid chromatography; MALDI-TOF, matrix-assisted laser desorption/
ionization–time of flight; MS, mass spectrometry; and MS/MS, tandem mass 
spectrometry.
Table 3. Metabolomics Study Design and Implementation 
Considerations
Study Component Considerations
Study design Prospective vs retrospective
Cohort vs case-control
Appropriate control group
Sample collection Fasting status and length of time of 
fasting
Consistency of collection protocol 
across the study cohort
Time between sample collection and 
processing
Time between sample collection and 
freezing to <−70°C
Protocols for sample preparation, 
depending on type of tissue
Type of storage tubes and caps used
Automated vs manual sample handling 
methods used for dividing into aliquots
Total storage time and conditions 
before profiling (eg, number of freeze-
thaw cycles)
Data collection Concomitant medication use
Dietary history (acute and chronic)
Environmental factors
Clinical comorbidities and outcomes
Metabolomic profiling Sensitivity of platform being used
Quality control measures (repeat 
samples, pooled samples, standards)
Metabolite identification methods (for 
nontargeted data)
Biological and analytical 
reproducibility
Statistical analysis Quality control assessment
Missing values, values below lower 
limits of detection
Outliers
Batch effects
Multiple comparisons
Multidimensional data reduction 
approaches
Supervised vs unsupervised analyses
Potential clinical and measurable 
confounders (comorbidities, renal 
function, medications, fasting status)
Assessment of independent and 
incremental association
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presence and abundance of hexose isomers (eg, common mol-
ecules such as fructose and galactose) and hexoses that are 
rarely reported (eg, tagatose, allose, or idose). Alternatively, 
such metabolites are easily separated by gas chromatography 
when detected in human biofluids. Therefore, comprehensive 
and unbiased interrogation of the human metabolome will 
likely require multiple complementary methods.
Bioinformatics and Statistical Considerations
As seen with genomics, the promise of any profiling technol-
ogy is fully realized only in the setting of a computational 
infrastructure that is capable of managing the vast amount 
of high-dimensional data generated. Robust approaches for 
storage, integration, statistical analyses, and visualization of 
metabolomics data remain in the early stages of development. 
Thus, the need for data tools is of particular importance in deal-
ing with untargeted metabolomics, in which both the volume 
and complexity of data can scale by multiple orders of magni-
tude, especially when applied to large population-level studies.
Data Processing
Central to metabolomics is the actual collection and handling 
of either MS or NMR data. Particularly with mass spectra, data 
processing can involve a number of critically important steps, 
including filtering background noise, detecting and defining 
thousands of spectral peaks from a single sample, and align-
ing spectra across multiple samples to allow comparison of 
metabolite features across sample groups. Although dozens of 
open-source and commercial tools have been used to process 
and report the results of MS- or NMR-based metabolomics 
data,47 there remains little uniformity or standardization from 
platform to platform, often complicating efforts to perform 
independent replication of metabolomics findings.
Data processing and robust analyses are much more dif-
ficult for untargeted metabolomics than for targeted metabolo-
mics. Existing widely used software packages have recognized 
limitations, including the most recent version of MS-DIAL, 
which can be used for data-independent mass fragmentations 
(SWATH-type data acquisitions), and classic software such as 
MZmine or XCMS. Although MS-DIAL excels in combin-
ing the different adducts and potential in-source fragments of 
all compounds on the level of intact molecules, in contrast to 
simple mass-to-charge (m/z) and retention time (rt) feature-
finding software such as XCMS, MS-DIAL has not yet been 
benchmarked against alternative software (eg, MZmine) with 
respect to achieving lower rates of false-negative and false-
positive peak finding results. Accordingly, caution is advised 
in the interpretation of reports of thousands of distinct metab-
olites present in a single LC-MS run, which may result from 
poor software performance and a high number of chemical 
noise peaks that are not derived from a truly biological back-
ground. As the field of metabolomics continues to advance, 
so too will data processing approaches as part of ongoing col-
lective efforts to ensure the robustness and reproducibility of 
findings across laboratories.
Data Analyses
Similar to issues in data processing, there currently exists little 
uniformity in the biostatistical management and analysis of 
metabolomics data. Statistical challenges for handling and 
analyzing metabolomics data are similar to those for other 
large-scale profiling data but also include several unique fea-
tures. Metabolomics measures are influenced by time-depen-
dent factors, including short-term and long-term perturbations 
or exposures that will influence detectable levels of metabo-
lites to varying degrees. Time-dependent factors may or may 
not contribute to variable missingness of values. Statistical 
approaches to handling missing data, especially for mea-
surements obtained from a broad untargeted metabolomics 
method, need to consider technical and biological contribu-
tions to missingness. Measurement values for individual ana-
lytes can be missing because they are below the lower limit 
of detection of a given platform, because of technical issues 
not specifically related to detection limits, or because they are 
truly biologically absent in a given tissue sample. Accordingly, 
the rate of missingness for an analyte profiled across a human 
cohort is often, but not always, correlated with the relative 
abundance of that analyte in samples obtained from that 
cohort. How to best handle metabolomics data depends on the 
nature and distribution of measurement values, including rates 
and types of missingness (eg, missing not at random). Thus, 
imputation approaches to handling missingness may be appro-
priate for some situations and not for others.
Beyond issues related to how metabolite variables are han-
dled, a number of different approaches have been used to iden-
tify potentially biological meaningful relationships between 
metabolites and clinical outcomes of interest in univariate and 
multivariable analyses. A traditional approach that is com-
monly applied involves analyzing each metabolite separately 
and adjusting for multiple comparisons across the number of 
metabolites studied with Bonferroni or false discovery rate 
thresholds. Given collinearity between metabolites, reflecting 
shared biological pathways and shared environmental per-
turbations, data reduction approaches are often additionally 
applied to reduce the statistical burden of multiple compari-
sons. An advantage of data reduction approaches is that the 
identification of interrelated groups of metabolites can high-
light underlying biology in ways that prioritization of single 
metabolite analysis cannot. Such approaches include but are 
not limited to principal components analysis and hierarchical 
cluster analyses. Complementary methods that are optimized 
for feature selection or prediction and are particularly suitable 
for high-dimensional data include discriminant analysis, par-
tial least-squares analysis, least absolute shrinkage and selec-
tion operator and related analyses, rule-based approaches (eg, 
random forests), and instance-based approaches (eg, support 
vector machines). The relative advantages and disadvantages 
of different statistical approaches can be understood on the 
basis of several features: (1) the extent to which a dimension 
reduction step is either required or not required before associ-
ation analyses, (2) the extent to which metabolite associations 
are assumed to be linear or nonlinear, (3) the extent to which 
prediction of an outcome versus variable selection is favored, 
and (4) the desire for sparseness in the predictive model ver-
sus identification of the larger set of correlated analytes for 
biological interpretation. Not all statistical approaches are 
efficient to run with standard computing resources, particu-
larly those that involve recursive modeling, and so practical 
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considerations are also involved in the selection of the most 
appropriate approach for a given dataset. Notably, commonly 
used methods have yet to be formally evaluated in compari-
son to each other for analyzing high-dimensional metabo-
lomics data acquired from either large or small cohorts. It 
is possible that a combination of statistical methods (eg, 
ensemble approach) may be desirable for some data sets. For 
approaches that require a dimension reduction step, the extent 
to which this initial stage of analysis should be unsupervised 
or supervised to account for intercorrelations between metab-
olite variables is not entirely clear and depends on the purpose 
of the study. The next generation of discoveries in metabolo-
mics will rely heavily on progress made to establish robust 
statistical methods for analyzing these high-dimensional data 
and improvements in the annotation of metabolite-related bio-
chemical pathways to enable in silico pathway analyses.
Data Reporting
With respect to reporting metabolomics data and results, 
standardization is also greatly needed. Metabolomics data 
reporting procedures should ideally include a universally 
accepted set of minimal criteria to be used in all published 
reports, including detailed methods and quality control met-
rics. Additionally, efforts should make use of standard pooled 
quality control samples. These control samples could include 
the National Institute of Standards & Technology Standard 
Reference Material 1950 standard plasma, which would also 
enable researchers to compare results, including use of untar-
geted metabolomics methods for which abundance of small 
molecules could be reported in relation to abundances found 
in that standard plasma. In addition, publication requirements 
should ensure the deposit of all metabolomics data, includ-
ing raw and processed data, in a central publicly accessible 
repository, as is currently required for other “omics” data. In 
the absence of raw data, verification of metabolite identifi-
cations cannot be performed by independent reviewers, and 
scientific claims may not be reproducible. Additionally, a 
centralized storage of metabolomics data provides opportuni-
ties for secondary analysis and data mining, ensuring the con-
tinued value of generated data sets. Such repositories will be 
essential for uncovering new metabolite correlates and detail-
ing the dynamic range of metabolites across populations and 
samples. It should be noted that achieving this priority may 
be complicated by the dependence of some groups on third-
party clinical research organizations from which raw spectral 
data are generally not available, making independent verifica-
tion impossible. In anticipation of the need for a central data 
repository, the National Institutes of Health has implemented 
a metabolomics repository for Common Funds projects that 
is open also for general purpose metabolomics48 and is highly 
endorsed for National Institutes of Health–funded studies. A 
similar resource has also been established in Europe.48a
Moving forward, efforts must be made across the field 
to include distinct database identifiers in metabolomics 
reports, at a minimum in supplemental tables. It is a com-
mon misconception that metabolite names are unique. For 
some compounds, up to hundreds of names exist; indeed, for 
most compounds, at least a dozen different names have been 
reported, often with overlapping use. A continued practice of 
using names as chemical identifiers leads to ambiguity and 
also severely hampers electronic retrieval of findings such 
as from PubMed searches. Instead, the National Institute of 
Standards & Technology and International Union of Pure 
and Applied Chemistry have defined a standardized, open-
source way to encode chemical structures into a simple string 
of letters, the International Chemical Identifier code. This 
code is accompanied by a very short International Chemical 
Identifier key that fits easily into tables and documents to 
facilitate automated searches.
Current Challenges
To ensure that metabolomics can realize its potential to sub-
stantially affect research and practice, experts in the field are 
currently addressing key challenges in implementation and 
application, including high-throughput approaches to extend 
profiling capacity; strategies for determining the biochemical 
identity and, in turn, the functional role of novel analytes; and 
methods for determining the true clinical importance of ana-
lytes observed in association with cardiovascular phenotypes.
High-Throughput Metabolomics
As tools for applying metabolomics to larger-scale cohorts are 
developed, so too will the utility of metabolomics and meta-
bolic markers in clinical practice. This is especially true of 
untargeted metabolomics applied to population-based stud-
ies, an essential step for defining the human metabolome and 
providing new knowledge of the biochemical landscape of 
health and disease. Because untargeted metabolomics allows 
monitoring thousands of metabolite features and assuming 
that metabolite-disease effect sizes will be comparable to 
those observed in targeted metabolomics studies, application 
across much larger cohorts than those previously studied will 
be needed to limit false-negative errors. In turn, the ability 
to profile multiple separate cohorts will be needed to validate 
findings and to limit false-positive errors. Given these impera-
tives, emerging high-throughput technologies must leverage 
higher-selectivity mass analysis and maintain acceptable lev-
els of reproducibility and sensitivity while scaling capacity.
Until recently, high-scale sample throughput was achiev-
able only with NMR-based approaches, which are tech-
nically robust, are amendable to automation, and do not 
require extensive upfront sample preparation.49 However, 
NMR approaches have limited sensitivity for detecting low-
abundancy metabolites. Thus, extending from NMR to more 
comprehensive measures of the metabolome with MS-based 
techniques represents the next challenge in throughput tech-
nology. Typically, MS-based approaches require coupling 
to chromatographic methods to reduce sample complexity 
before introduction into a mass spectrometer. Although very 
effective, chromatographic methods are often time consum-
ing, especially when serial chromatography is applied to each 
sample to capture representative molecules across very differ-
ent chemical classes in a discovery mode (ie, subplatforms). 
Given the costs associated with obtaining and operating an 
MS infrastructure and the need for trained personnel to man-
age such instrumentation, extended analytic times can trans-
late into substantial cost per sample. Time- and cost-related 
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limitations will, in part, be overcome with the recently estab-
lished National Institutes of Health Regional Comprehensive 
Metabolomics Resource Cores and the development of similar 
academic and commercial facilities capable of multiplexing 
metabolomics studies. As seen over the past decade in the field 
of genomics, the currently high cost per sample of metabo-
lomics profiling is expected to decline over the next several 
years as throughput technologies continue to develop.
Technical advances, including the integration of ultrath-
roughput high-resolution MS with automated sample handling 
and computational identification of mass spectral features, are 
facilitating the transition to an era when thousands of samples 
can be analyzed in a short time, with the measure of thou-
sands of metabolites per specimen. Such throughput applied 
to large-scale studies will allow characterization of chemical 
diversity across multiple racial/ethnic populations in relation 
to prospective disease phenotypes and in conjunction with 
integrated data on genomic variation, epigenetic markers, 
mRNA transcription, and other biomarkers to enable a true 
systems-level analysis of human physiology and disease.
Biochemical Identity and Role of Novel Metabolites
Early chemoinformatics approaches have been developed to 
aid in metabolite identification and data visualization, although 
existing tools remain relatively rudimentary. Thus, improve-
ment in experimental and computational tools designed to 
clarify the identity and role of novel metabolites represents 
an important future challenge for the field. With untargeted 
analysis of any complex human biospecimen, only a minor-
ity fraction of the metabolites is definitively identifiable by 
current standards, with the majority of molecules remaining 
unknown with respect to structure and origin (ie, endogenous 
versus exogenous). Future technical advances in MS may 
aid in molecular identification, including differential mobil-
ity spectrometers that could be placed between an LC and an 
MS instrument that could further extend metabolomic cover-
age and theoretically assist with compound identification. At 
present, a number of spectral databases currently exist47 and 
serve as invaluable resources. Expanding these databases, 
along with computational methods for predicting metabolite 
identification, will be essential for progress in the field. To 
guide database and computational methods development, the 
Metabolomics Standards Initiative has put forward criteria 
for reporting of metabolites that importantly include the level 
of rigor used for identification of metabolites.49a Because the 
practice of metabolomics extends from the analytical chem-
ist to the mainstream biologist, additional data analysis and 
visualization tools will be needed to facilitate scientific discov-
ery as well as communication, including those tools allowing 
pathway analysis or metabolite set enrichment analysis, as well 
as correlation-based network analysis. Sophisticated methods 
for mapping metabolomics data to pathways will be critical 
for interrogating not only interanalyte relationships but also 
metabolite relationships with genomic, epigenetic, transcrip-
tomic, and proteomic factors, as well as clinical phenotypes.
Clinical Relevance
Metabolomics studies conducted in population-based cohorts 
will allow studies of how various factors, including diet and 
medical comorbidities, affect the metabolome. As has been dem-
onstrated with metabolomic studies of oral glucose challenge, 
acute caloric intake, and the attendant stimulation of insulin sig-
naling, select metabolic interventions have a profound impact 
on circulating metabolites. Much less is known about how 
differences in dietary composition modulate the metabolome 
chronically and acutely. Indeed, the majority of metabolomics 
biomarker studies to date have examined plasma obtained from 
fasting individuals and thus are agnostic to effects of metabolite 
variation in the fed or challenged state. Disentangling the rela-
tive contribution of various medical comorbidities to circulating 
metabolite levels is also important in assessment of the potential 
value of select metabolites as markers of CVD risk. In addition 
to having a causal role in CVD pathogenesis, diabetes mellitus 
and obesity have a substantial impact on the metabolome that 
can confound metabolomics studies of CVD prediction. Perhaps 
less appreciated is the substantial impact that kidney disease 
can have on both CVD risk and circulating metabolite levels. 
Although recognized for their ability to excrete select nitrog-
enous metabolites such as creatinine and urea, the kidneys also 
exert broad and heterogeneous effects, depending on the extent 
to which metabolites of interest are filtered, absorbed, secreted, 
catabolized, or even synthesized by the kidney.50 Ultimately, a 
full accounting of diet, medical comorbidities, and other poten-
tial confounders in metabolomics studies of CVD will require a 
variety of approaches. First, metabolomics data acquired from 
large, well-phenotyped cohorts are required to establish the 
matrix of correlations between metabolite levels and clinical 
variables known to be associated with cardiometabolic disease 
(eg, age, race, sex, body size, insulin resistance, blood pressure, 
and renal function). Second, more in-depth studies of individ-
uals over time are required to clarify how fasting versus fed 
status, dietary patterns, circadian cycles, other time-dependent 
factors, and random variation can affect circulating metabolites. 
Third, although less important from a strict biomarker sense, 
studies that use invasive catheterization of select vascular beds 
are important to establish the potential organ specificity of 
select peripheral venous metabolite signatures. Finally, under-
standing the genetic determinants of plasma metabolite levels 
and cross-referencing with prior genetics studies of CVD offer 
the potential to implicate select metabolite biomarkers in causal 
pathways.
Future Directions
With continued advancement in metabolomic technolo-
gies, several possible applications in cardiovascular medi-
cine may be on the horizon. With respect to understanding 
the pathophysiology of disease, integration of genomic and 
metabolomic data could allow clinicians and researchers to 
better explain why an individual develops CVD in response 
to a given exposure history such as tobacco or chronic stress. 
For example, sources of interindividual variation in response 
to risk exposures could include the possibility that a spe-
cific metabolite is not produced as a result of exposure to the 
stimulus or is produced but degraded at a different rate. With 
respect to risk prediction, the ability to one day perform actual 
or nearly real-time monitoring of blood or urine metabolites 
could allow clinicians to detect small-molecule biomarkers 
associated with worsening or improving clinical trajectories 
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and to target early interventions. Similarly, changes in metab-
olite profiles over time, with aging, or after administration of 
a drug could be used to define an individual’s predisposition 
for disease and response to therapy. Ultimately, the ability to 
efficiently and effectively use metabolomics tools to conduct 
molecular phenotyping could serve to substantially advance 
the goals of precision medicine.
The promise that metabolomics offers for improving med-
ical diagnostics and therapeutics notwithstanding, advances 
in the field will depend on overcoming certain intrinsic chal-
lenges. The tractable number of metabolites potentially mea-
surable in the metabolome is a potential analytic advantage 
over other detailed profiling assays such as genomics and 
proteomics.51 On the other hand, the complexity of metabo-
lite profiling exceeds that of other profiling techniques such 
as genomics or transcriptomics, given that the basic chemi-
cal constituents of DNA or mRNA are far less diverse. The 
inability of basic investigators to transparently convey the 
challenges intrinsic to the field, combined with the clinical 
community’s desire for rapid integration of new technologies, 
has led to an initial mismatch of expectations and “metabolo-
mic deliverables.” However, this divide between expectation 
and deliverables is beginning to narrow. Protocols for evalu-
ating major classes of compounds have become increasingly 
more standardized. Authentic chemical standards for provid-
ing absolute quantitation of analytes have been integrated into 
these protocols, throughput technologies have become more 
powerful, and databases for compound identification have 
become more robust. In turn, standardized procedures are 
increasingly being applied to large clinical cohorts, including 
individuals representing the spectrum of cardiovascular and 
metabolic disease risk. As a result, the scientific community 
is fortunately beginning to see consistency in the findings 
reported from across different metabolomics studies. Beyond 
feasibility and reliability, however, the ultimate challenge per-
tains to exactly how much new information metabolomics will 
add to established diagnostic approaches and tests, the critical 
bar for any nascent technology.
The next generation of scientific discoveries will emerge 
from an improved understanding of the mechanisms underly-
ing disease risk and phenotypes at the individual level.52 Given 
the potential of metabolomics to integrate detailed biochemi-
cal information with data on both endogenous and exogenous 
exposures, metabolomics also offers the opportunity to bridge 
the methodological and informational gap between the fields 
of genomics and environmental science in particular.53,54 Such 
an integrated approach to understanding and targeting the 
links between genetic predisposition and external risk expo-
sures is especially needed for complex and multifactorial dis-
ease entities such as CVD.
Summary
Having evolved considerably from traditional analytical 
chemistry, metabolomics now provides extremely detailed 
molecular profiling of biospecimens and offers an integrated 
approach to investigating both the intrinsic and extrinsic fac-
tors that contribute to CVD risk. Early work in the field has 
led to the discovery of novel molecular markers of CVD 
risk, including metabolites related to dietary patterns and gut 
microbiome activity. Future work will leverage ongoing tech-
nical advances, which are widening the scope and through-
put with which small-molecule profiling can be conducted. 
Therefore, the prospects for further discovery are rapidly 
growing. Nonetheless, the extent to which metabolomics 
work will yield a next generation of important discoveries in 
cardiovascular science will depend on the success with which 
the field can address key challenges, including bioinformatics 
approaches for handling high-throughput untargeted metabo-
lomics data, strategies for identifying the biochemical struc-
ture and functional role of novel metabolites, and methods 
for determining the true relevance of metabolites observed in 
association with clinical outcomes. Progress made in address-
ing these challenges will allow the potential for metabolomics 
approaches to substantially affect diagnostics and therapeutics 
in cardiovascular medicine.
Appendix
Appendix. Requirements Necessary to Transition Metabolomics 
From Research Applications to Clinical Diagnostics
Component Considerations
Guidance 
documents
Structure for good laboratory practices needs to be 
established
Input needed from metabolomics experts
Input needed from clinical laboratories
Input needed from regulatory agencies
Regulatory 
structure
Laboratory standards need to be established
Laboratory inspection protocols need to be developed
Proficiency testing materials need to be developed
Laboratory inspectors need to be trained
Reimbursement needs to be defined
Clinical 
concerns
Patients who will benefit from metabolic profiling need 
to be identified
The clinical utility of testing needs to be defined
The safety and efficacy of the testing for individual 
patients need to be demonstrated
Analytical 
considerations
Patient preparation needs to be defined
Protocols need to be standardized
Performance of tests needs to be compared with 
established techniques
Standard reference materials need to be developed for 
harmonization (eg, National Institute of Standards & 
Technology)
Proficiency materials need to be developed
Quality control metrics need to be developed
Expected ranges for different patient populations need 
to be defined
Education Physicians need to be trained on clinical utility
Laboratories need to gain expertise in analysis
Insurers (payers) need to understand clinical value of testing
Quality control Consensus documents on degree of control are needed (eg, 
with untargeted metabolomics, how to monitor recovery 
and relative concentration for unknown metabolites)
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